996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Basic Info

  • Grade: Pharmaceutical Grade

    Factory Location: QUANZHOU

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Bictegravir is a novel integrase inhibitor developed by Gilead Sciences scientists. In vitro and clinical results were produced by Gilead in the summer of 2016. As of June 2016, Bictegravir was used as a single tablet regimen in combination with tenofovir alafinamide (TAF) and emtricitabine (FTC) for the treatment of hiv-1 infection.

    Indication: HIV-1 infection

    All the products under the patent are only for R&D use.

    Patent from Gilead Sciences, expiry date(The U.S):Dec.19,2033

     

Send your message to this supplier
  • From:
  • To:
    Quanzhou Fortune Biopharma Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service